Trifecta Capital Advisors LLC Buys 1,576 Shares of Johnson & Johnson $JNJ

Key Points

• Trifecta Capital Advisors LLC increased its stake in Johnson & Johnson by 64.5%, acquiring an additional 1,576 shares, bringing its total holdings to 4,021 shares valued at approximately $614,000.
• Analysts have raised their price targets for Johnson & Johnson, with Goldman Sachs increasing it from $186.00 to $212.00 and Citigroup lifting theirs from $200.00 to $213.00, suggesting a positive outlook for the stock.
• Johnson & Johnson reported a net margin of 25.00% and a return on equity of 32.49%, with earnings of $2.26 per share, indicating strong financial performance for the quarter.

Trifecta Capital Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 64.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,021 shares of the company's stock after buying an additional 1,576 shares during the quarter. Trifecta Capital Advisors LLC's holdings in Johnson & Johnson were worth $614,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Brighton Jones LLC lifted its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $218,000. GAMMA Investing LLC raised its holdings in shares of Johnson & Johnson by 48.0% in the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock valued at $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Davis Investment Partners LLC raised its holdings in shares of Johnson & Johnson by 7.9% in the 1st quarter. Davis Investment Partners LLC now owns 4,429 shares of the company's stock valued at $682,000 after purchasing an additional 326 shares in the last quarter. Finally, Yarger Wealth Strategies LLC raised its holdings in shares of Johnson & Johnson by 6.2% in the 1st quarter. Yarger Wealth Strategies LLC now owns 1,560 shares of the company's stock valued at $259,000 after purchasing an additional 91 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on JNJ. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a report on Thursday. Barclays boosted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Weiss Ratings raised shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday. Finally, Citigroup lifted their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a "buy" rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $192.94.

Johnson & Johnson Stock Down 0.2%

NYSE:JNJ opened at $190.66 on Friday. The company has a market cap of $459.16 billion, a PE ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's 50 day moving average is $178.48 and its two-hundred day moving average is $163.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.